Search

Your search keyword '"Kinuya, Seigo"' showing total 1,184 results
Start Over Author "Kinuya, Seigo"
1,184 results on '"Kinuya, Seigo"'

27. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

Author

Inaki, Anri, Shiga, Tohru, Tsushima, Yoshito, Jinguji, Megumi, Wakabayashi, Hiroshi, Kayano, Daiki, Akatani, Norihito, Yamase, Takafumi, Kunita, Yuji, Watanabe, Satoru, Hiromasa, Tomo, Mori, Hiroshi, Hirata, Kenji, Watanabe, Shiro, Higuchi, Tetsuya, Tomonaga, Hiroyasu, and Kinuya, Seigo

Published
2022
Full Text
View/download PDF

33. Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer.

Author

Inaki, Anri, Mizokami, Atsushi, Wakabayashi, Hiroshi, Izumi, Kouji, Kadono, Yoshifumi, Toyama, Tadashi, Takahara, Shizuko, Murayama, Toshinori, and Kinuya, Seigo

Abstract

Background: Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals allow whole-body imaging to detect prostate cancer (PC). Positron emission tomography imaging using gallium-68 (68Ga)-PSMA-11 has been shown to have a favorable safety and tolerability profile and high diagnostic performance. The study evaluates the safety and pharmacokinetics of 68Ga-PSMA-11 in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer. Methods: This single arm study enrolled Japanese patients with primary PC (n = 3), suspected recurrent PC following radical prostatectomy (n = 4), or suspected recurrent PC following radical radiotherapy (n = 3). All patients received a single intravenous dose of 68Ga-PSMA-11 2.0 MBq/kg (±10%) followed by PSMA PET imaging and safety and pharmacokinetic evaluations. Based on the blood concentrations of 68Ga-PSMA-11 and the radioactivity distribution rate in each organ/tissue, the absorbed doses in major organs/tissues and the whole-body effective dose were calculated by the Medical Internal Radiation Dose method. Results: Ten patients were enrolled. Mean age was 73.3 ± 4.8 years, and median prostate-specific antigen was 8.250 ng/mL. Five patients (50%) experienced a total of 6 adverse events, and no grade ≥ 2 adverse events or serious adverse events were reported. No clinically significant changes in vital signs, haematology parameters, or blood chemistry or ECG abnormalities were observed. The estimated whole body effective dose of 68Ga-PSMA-11 (mean ± standard deviation) was 2.524 × 10–2 ± 2.546 × 10–3 mSv/MBq. Time to maximum concentration (1.16 × 10–4 ± 1.3 × 10–5% ID/mL) in whole blood was 2.15 ± 0.33 min. Conclusions: 68Ga-PSMA-11 has a favourable safety and tolerability profile in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer, which is comparable to previous observations in other populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor.

Author

Echigo, Hiroaki, Munekane, Masayuki, Fuchigami, Takeshi, Washiyama, Kohshin, Mishiro, Kenji, Wakabayashi, Hiroshi, Takahashi, Kazuhiro, Kinuya, Seigo, and Ogawa, Kazuma

Subjects
PEPTIDES, PHARMACOKINETICS, MOIETIES (Chemistry), COMPUTED tomography, TREATMENT effectiveness, GIBBERELLINS
Abstract

Purpose: A probe for targeted alpha therapy (TAT) using the RGD peptide (Ga-DOTA-K([211At]APBA)-c(RGDfK) ([211At]1)) with albumin-binding moiety (ABM) was recently developed. [211At]1 highly accumulated in tumors and significantly inhibited tumor growth in U-87 MG tumor-bearing mice. However, high [211At]1 retention in blood may cause critical adverse events, such as hematotoxicity. Therefore, we attempted to accelerate the blood clearance of [211At]1 by competitively inhibiting the binding of [211At]1 to albumin to modulate the pharmacokinetics of the former. Methods: To evaluate the effects of albumin-binding inhibitors in normal mice, sodium 4-(4-iodophenyl)butanoate at 2, 5, or 10 molar equivalents of blood albumin was administered at 1-h postinjection of [211At]1. The biodistribution of [211At]1, SPECT/CT imaging of [67Ga]Ga-DOTA-K(IPBA)-c(RGDfK) ([67Ga]2), and the therapeutic effects of [211At]1 were compared with or without IPBA administration in U-87 MG tumor-bearing mice. Results: Blood radioactivity of [211At]1 was decreased in a dose-dependent manner with IPBA in normal mice. In U-87 MG tumor-bearing mice, the blood radioactivity and accumulation in nontarget tissues of [211At]1 were decreased by IPBA. Meanwhile, tumor [211At]1 accumulation was not changed at 3-h postinjection of IPBA. In SPECT/CT imaging of [67Ga]2, IPBA administration dramatically decreased radioactivity in nontarget tissues, and only tumor tissue was visualized. In therapeutic experiments, [211At]1 with IPBA injected-group significantly inhibited tumor growth compared to the control group. Conclusion: IPBA administration (as an albumin-binding inhibitor) could modulate the pharmacokinetics and enhance the therapeutic effects of [211At]1. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors

Author

Kobayashi, Noritoshi, Takano, Shoko, Ito, Kenichi, Sugiura, Madoka, Ogawa, Matsuyoshi, Takeda, Yuma, Okubo, Naoki, Suzuki, Akihiro, Tokuhisa, Motohiko, Kaneta, Tomohiro, Utsunomiya, Daisuke, Hata, Masaharu, Inoue, Tomio, Hosono, Makoto, Kinuya, Seigo, and Ichikawa, Yasushi

Published
2021
Full Text
View/download PDF

40. Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents

Author

Uemura, Hirotsugu, Masumori, Naoya, Takahashi, Shunji, Hosono, Makoto, Kinuya, Seigo, Sunaya, Toshiyuki, Horio, Tomoyo, Okayama, Yutaka, and Kakehi, Yoshiyuki

Published
2021
Full Text
View/download PDF

42. Clinical practice guidelines for high-resolution breast PET, 2019 edition

Author

Satoh, Yoko, Kawamoto, Masami, Kubota, Kazunori, Murakami, Koji, Hosono, Makoto, Senda, Michio, Sasaki, Masayuki, Momose, Toshimitsu, Ito, Kengo, Okamura, Terue, Oda, Keiichi, Kuge, Yuji, Sakurai, Minoru, Tateishi, Ukihide, Fujibayashi, Yasuhisa, Magata, Yasuhiro, Yoshida, Takeshi, Waki, Atsuo, Kato, Katsuhiko, Hashimoto, Teisuke, Uchiyama, Mayuki, Kinuya, Seigo, Higashi, Tatsuya, Magata, Yasuhiro, Machitori, Akihiro, Maruno, Hirotaka, Minamimoto, Ryogo, and Yoshinaga, Keiichiro

Published
2021
Full Text
View/download PDF

45. Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma.

Author

Mori, Hiroshi, Wakabayashi, Hiroshi, Saito, Shintaro, Nakajima, Kenichi, Yoshida, Kotaro, Hiromasa, Tomo, and Kinuya, Seigo

Subjects
PARAGANGLIOMA, LUNGS, PHEOCHROMOCYTOMA, MAGNETIC resonance imaging, RECEIVER operating characteristic curves, METASTASIS, DUAL-energy X-ray absorptiometry, MAGNETIC resonance mammography
Abstract

This study aimed to compare tumor lesion detectability and diagnostic accuracy of whole-body magnetic resonance imaging (WB-MRI) and radioiodine-labeled meta-iodo-benzylguanidine (mIBG) imaging techniques in patients with metastatic pheochromocytoma and paraganglioma (PPGL). This retrospective study included 13 patients had pheochromocytoma and 5 had paraganglioma, who were all suspected of having metastatic tumors. Each patient underwent WB-MRI and 123I-mIBG as a pretreatment screening for 131I-mIBG therapy. Two expert reviewers evaluated WB-MRI, 123I-mIBG images, and post-therapy 131I-mIBG images for the presence of metastatic lesions in the lungs, bones, liver, lymph nodes, and other organs. Diagnostic measures for detecting metastatic lesions, including sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristics (ROC)—area under the curve (AUC), were calculated for each imaging technique. We analyzed WB-MRI images for detecting metastatic lesions, which demonstrated sensitivity, specificity, accuracy, PPV, NPV, and AUC of 82%, 97%, 90%, 96%, 86%, and 0.92, respectively. These values were 83%, 95%, 89%, 94%, 86%, and 0.90 in 123I-mIBG images and 85%, 92%, 89%, 91%, 87%, and 0.91 in post-therapy 131I-mIBG images, respectively. Our results reveal the comparable diagnostic accuracy of WB-MRI to one of the mIBG images. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition).

Author

Watabe, Tadashi, Namba, Masao, Yanagida, Sachiko, Nakamura, Yoshihide, Yamada, Takahiro, Tatsuno, Saori, Ri, Aritoshi, Yoshida, Shuhei, Uyama, Kumiko, Kinuya, Seigo, Tomiyama, Noriyuki, and Hosono, Makoto

Abstract

Recently, an astatine-labeled prostate-specific membrane antigen (PSMA) ligand ([211At]PSMA-5) has been developed for the targeted alpha therapy of patients with prostate cancer. This manual delineates its physicochemical characteristics to assist healthcare professionals in understanding the α-ray-emitting drug of [211At]PSMA-5 when administered to patients. The safety considerations regarding the handling and use of this drug in clinical trials are outlined, based on the proper usage manual of previous studies. The dose limits, as defined by the guidelines of the International Commission on Radiological Protection (ICRP) and the International Atomic Energy Agency (IAEA), are assessed for patients' caregivers and the general public. According to the calculations provided in this manual, clinical trials involving [211At]PSMA-5 can be safely conducted for these populations even if patients are released after its administration. Moreover, this manual provides comprehensive guidance on the handling of [211At]PSMA-5 for healthcare facilities, and compiles a list of precautionary measures to be distributed among patients and their caregivers. While this manual was created by a research team supported by Ministry of Health, Labour, and Welfare in Japan and approved by Japanese Society of Nuclear Medicine, its applicability extends to healthcare providers in other countries. This manual aims to facilitate conducting clinical trials using [211At]PSMA-5 in patients with prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results